Organon Acquired by Sun Pharmaceutical Industries | Healthcare M&A Deal

Sun Pharmaceutical Industries has acquired Organon, a pharmacy business in New Jersey, for $11.75 billion. Sun Pharmaceutical Industries acquisitions focus on expanding healthcare M&A in women’s health and biosimilars through the Organon acquisition of a New Jersey-based pharmaceutical company. Organon, spun out from Merck in 2021, brings established capabilities in women’s health and biosimilars that support Sun Pharmaceutical Industries’ platform acquisition strategy. The strategic acquisition is structured as an all-cash deal for all outstanding shares at $14.00 per share, valuing Organon including debt, and is positioned as a platform acquisition within broader healthcare deals NJ.